Background The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …

Background Pathogenic variants of the DPYD gene are strongly associated with grade≥ 3
toxicity during fluoropyrimidine chemotherapy. We conducted a systematic review and meta …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained
limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx …

Purpose Fluoropyrimidines are frequently prescribed anticancer drugs. A polymorphism in
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …

Background Previous studies have suggested the potential importance of three DPYD
variants (DPYD* 2A, D949V, and I560S) with increased 5-FU toxicity. Their individual …

Background Adjuvant fluoropyrimidine-based chemotherapy substantially reduces
recurrence and mortality after resection of stage 3 colon cancer. While standard doses of 5 …

Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed
anticancer drugs. They are inactivated in the liver by the enzyme dihydropyrimidine …

Fluoropyrimidines are widely used in the treatment of several types of solid tumors. Although
most often well tolerated, severe toxicity is encountered in~ 20–30% of the patients …

PURPOSE DPYD-guided fluoropyrimidine dosing improves patient safety in carriers of
DPYD variant alleles. However, the impact on treatment outcome in these patients is largely …